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SARS-CoV-2 is a novel virus that has spread around the world. 
Its clinical presentation ranges from asymptomatic or mild viral 
infection to severe, life-threatening hypoxic pneumonia.[1-4] As it is a 
novel condition, pharmacological treatment regimens for COVID-19 
are varied and largely experimental. At the time of writing (December 
2020), benefit had only been demonstrated with corticosteroids. [5] 
In general, antibiotics are the cornerstone of the management of 
community-acquired pneumonia, and their empirical use continues 
to be recommended in many guidelines and institutional protocols 
specific to COVID-19 pneumonia owing to challenges in conclusively 
ruling out bacterial coinfection.[6-8]
Bacterial superinfection is an important cause of disease 
severity and mortality in influenza. Streptococcus pneumoniae and 
Staphylococcus aureus are frequently implicated.[9] The concern that 
similar mechanisms may be at work in severe SARS-CoV-2 infection 
initially motivated the administration of empirical antibiotic therapy in 
patients admitted with COVID-19 pneumonia. A recent meta-analysis 
has shown low rates of bacterial coinfection and superinfection in 
hospitalised patients with COVID-19, ranging from 3% to 14%. These 
low rates have also been found in previous coronavirus epidemics,[10-12] 
but may not apply in settings with a higher burden of infectious disease 
including HIV and tuberculosis.[13-15]
Despite low rates of bacterial infection in patients with COVID-
19, antibiotic use remains high, with broad-spectrum agents pre-
dominantly being used, conferring dubious benefit.[16] The collateral 
damage associated with inappropriate antibiotic use is well described 
and includes increased morbidity, mortality and cost; the occurrence 
of side-effects, adverse events and toxicity; and contribution to 
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Background. Empirical broad-spectrum antibiotics are frequently prescribed to patients with severe COVID-19, motivated by concern about 
bacterial coinfection. There is no evidence of benefit from such a strategy, while the dangers of inappropriate antibiotics are well described.
Objectives. To investigate the frequency, profile and related outcomes of infections by bacterial pathogens in patients admitted to an 
intensive care unit (ICU) with severe COVID-19 pneumonia.
Methods. This was a prospective, descriptive study in a dedicated COVID-19 ICU in Cape Town, South Africa, involving all adult 
patients admitted to the ICU with confirmed COVID-19 pneumonia between 26 March and 31 August 2020. We collected data on patient 
comorbidities, laboratory results, antibiotic treatment, duration of admission and in-hospital outcome.
Results. We included 363 patients, who collectively had 1 199 blood cultures, 308 tracheal aspirates and 317 urine cultures performed. 
We found positive cultures for pathogens in 20 patients (5.5%) within the first 48 hours of ICU admission, while 73 additional patients 
(20.1%) had positive cultures later during their stay. The most frequently isolated pathogens at all sites were Acinetobacter baumannii 
(n=54), Klebsiella species (n=13) and coagulase-negative staphylococci (n=9). Length of ICU stay (p<0.001) and intubation (p<0.001) were 
associated with positive cultures on multivariate analysis. Disease severity (p=0.5), early antibiotic use (p=0.5), diabetes mellitus (p=0.1) and 
HIV (p=0.9) were not associated with positive cultures. Positive cultures, particularly for tracheal aspirates (p<0.05), were associated with 
longer ICU length of stay and mortality. Early empirical antibiotic use was not associated with mortality (odds ratio 2.5; 95% confidence 
interval 0.95 - 6.81).
Conclusions. Bacterial coinfection was uncommon in patients at the time of admission to the ICU with severe COVID-19. Avoiding early 
empirical antibiotic therapy is therefore reasonable. Strategies to avoid coinfection and outbreaks in hospital, such as infection prevention 
and control, as well as the strict use of personal protective equipment, are important to improve outcomes.
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anti biotic selective pressure driving the global threat of antibiotic 
resistance. [17-20] More judicious use of antibiotics with consideration 
for early discontinuation, in keeping with antibiotic stewardship 
principles, may therefore be appropriate to preserve these agents.
Objectives
To describe the frequency of bacterial coinfection and superinfection 
and pathogen distribution in adult patients admitted to an intensive 
care unit (ICU) with COVID-19 pneumonia. We assessed the impact 
on outcomes of bacterial coinfection and superinfection, and the 




We performed a prospective descriptive study involving all adult 
patients with confirmed COVID-19 admitted to the dedicated 
COVID-19 ICU at Tygerberg Hospital, Cape Town, South Africa, 
starting from the first case managed at our institution on 26 March 
2020 until the study end date on 31 August 2020, corresponding to 
our first wave.
Data collection
Data were extracted from medical records and entered into a Research 
Electronic Data Capture (REDCap) database.[21] We extracted 
information on patient comorbidities, laboratory results, treatment, 
duration of admission and outcomes from this database for analysis.
General patient management
In our ICU, patient management evolved in keeping with emerging 
evidence. Initially all patients received empirical broad-spectrum 
antibiotics (amoxicillin-clavulanate and azithromycin) until viral 
pneumonia was confirmed, a practice that ceased later in the 
pandemic. Meropenem was prescribed empirically for hospital-
acquired infections, defined as new infections occurring at least 48 
hours after admission. Per institutional protocol, all patients had 
blood cultures and tracheal aspirates performed on ICU admission 
with follow-up cultures done only when clinically indicated. Our 
ICU chose a strategy of initial high-flow nasal prong oxygen as 
our preferred mode to support oxygenation, with intubation and 
ventilation reserved for patients in whom this method failed.[22] 
Patients were initially managed with high-dose hydrocortisone or 
methylprednisolone, but following evidence from the RECOVERY 
trial,[5] lower doses of steroids (dexamethasone 8 mg intravenously) 
were used. There was very limited use of specific antiviral therapies 
(e.g. chloroquine and remdesivir).
Virological diagnosis
All cases of COVID-19 were confirmed by reverse transcriptase 
polymerase chain reaction for SARS-CoV-2, performed on 
respiratory isolates including nasal swabs, sputum and/or tracheal 
aspirates.
Identification of bacterial pathogens
All cultures were submitted to the on-site National Health Laboratory 
Service microbiology laboratory and processed using standard 
procedures entailing inoculation of basic agar plates, followed by 
overnight incubation and follow-up of relevant isolates for urine 
and respiratory samples. For blood cultures, the automated BacT/
Alert blood culture incubation system and BacT/Alert FA or FN Plus 
bottles (Biomérieux, France) are used. Blood cultures are incubated 
in the instrument as soon as possible after arrival in the laboratory. 
After flagging positive, a Gram stain is performed from the blood 
culture broth, clinicians are informed of the microscopy result, 
and appropriate media are inoculated for overnight incubation. 
Identification and antibiotic susceptibility testing of cultured isolates 
involves use of the automated VITEK 2 system (Biomérieux, France) 
and/or disc diffusion testing, which are interpreted using annually 
published Clinical Laboratory Standards Institute breakpoints. 
Manual methods of identification are used for identification in 
specific circumstances.
Classification of organisms
‘Contaminants’ are bacteria that are not actually present at the 
sample site, but are accidentally inoculated in the culture during 
collection or processing and give rise to a false-positive culture. 
‘Colonisers’ are bacteria that grow on a body surface exposed 
to the environment without causing any infection. Differentiating 
contaminants and colonisers from true pathogens is challenging. To 
address this, we predefined known said organisms (e.g. coagulase-
negative staphylococci (CoNS) and Bacillus cereus) as contaminants 
or colonisers if they were only cultured once, and pathogens if they 
were cultured more than once, in the same patient. Positive culture 
results were deduplicated based on the site of sample collection, with a 
positive result showing the same pathogen with the same susceptibility 
profile within a 14-day period considered a single episode.
Standardised definitions were used to classify antibiotic resis-
tance. [23] Multidrug resistance was defined as acquired non-
susceptibility to at least one agent in three or more antimicrobial 
categories. Extensive drug resistance (XDR) was defined as 
non-susceptibility to at least one agent in all but two or fewer 
antimicrobial categories. Pan-drug resistance (PDR) was defined as 
non-susceptibility to all agents in all antimicrobial categories.
Definitions
‘Pandemic time’ was defined as the number of days from 26 March 
2020 (admission of the first patient with COVID-19 to the ICU) to 
the day of the event.
In this article, ‘early culture’ refers to a culture performed within 
the first 48 hours of ICU admission. When culturing a pathogen, 
it usually indicates bacterial ‘coinfection’, defined as an infection 
occurring simultaneously with the viral infection and present at the 
time of presentation to hospital.
‘Late culture’ refers to a culture performed after 48 hours of 
admission to the ICU. When culturing a pathogen, it usually 
indicates bacterial ‘superinfection’, defined as a secondary infection 
superimposed on the initial viral infection and usually developing 
in hospital.
The ratio of arterial oxygen partial pressure to the fraction of 
inspired oxygen (P/F ratio) was used as a marker of disease severity.
Comorbidities were captured as recorded in the medical records by 
the primary clinician.
Outcome measures
The primary outcome measures were positive blood, urine and/or 
tracheal aspirate cultures. Secondary outcome measures included 
time to positive culture, length of stay, presence of antibiotic 
resistance and in-hospital mortality.
Statistical analysis
Statistical analysis was performed using R 3.6.2 (R Core Team, 
USA). Statistical significance was set at p<0.05 and a 95% confidence 
interval (CI) was used. Pearson’s χ2 test was used to identify 
associations between categorical variables and the outcomes of 
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interest. When comparing the means of continuous data, the t-test 
was used to assess normally distributed variables while the non-
parametric Wilcoxon rank-sum test was used to assess variables 
that did not follow a normal distribution pattern. To assess for 
independent factors associated with positive culture and mortality, 
multivariable logistic regression was used. Variables in the final 
model were selected based on the researchers’ subject knowledge, 
accounting for the number of parameters the model could support. 
To assess whether pandemic time was associated with positive culture 
or increasing levels of antibiotic resistance, we assessed various 
factors in a multivariable model adjusting for the effect of length of 
time in the ICU. Multivariate analyses are reported as odds ratios 
(ORs) with their corresponding 95% CIs.
Ethical considerations
The study was approved by the Health Research Ethics Committee of 
Stellenbosch University (ref. no. N20/04/002_COVID-19).
Results
We included 363 patients. Outcome data were available for all 
patients. The mean age (standard deviation (SD)) of the patients was 
53.4 (10.5) years. Comorbidities, admission oxygenation status and 
admission laboratory results are shown in Table 1.
Culture results
We extracted results for 1 199 blood cultures, 308 tracheal aspirates 
and 317 urine cultures. One hundred and thirty-three blood cultures 
(11.1%) in 65 patients, 54 tracheal aspirates (17.5%) in 42 patients 
and 19 urine cultures (6.0%) in 19 patients cultured pathogens.
In 20 patients (5.5%) pathogens were cultured on early cultures, 
while a further 73 patients (20.1%) had late cultures that were 
positive. The distribution by site is shown in Table S1 in the Appendix 
(supplementary file available at http://samj.org.za/public/sup/15590.
pdf). Late blood cultures were 15.4 times (95% CI 9.0 - 26.5) more 
likely to be positive than early blood cultures (p<0.0001), while late 
Table 1. Baseline characteristics of the study population
Characteristic
Age (years), mean (SD) 53.4 (10.5)
Comorbidities, n (%)
High body mass index 249 (68.6)
Hypertension 220 (60.6)
Diabetes mellitus 182 (50.1)
HIV-positive 53 (14.6)
CD4 count on admission (cells/µL), median (IQR) 295 (166 - 462)
Viral load (copies/mL), median (IQR) <40 (<40)
Dyslipidaemia 40 (11.0)
Asthma 18 (5.0)
Ischaemic heart disease 10 (2.8)
Current tuberculosis 2 (0.6)
Previous tuberculosis 24 (6.6)
Chronic kidney disease 14 (3.9)
Admission oxygenation status
PaO2 (kPa), median (IQR) 7.2 (6.0 - 8.9)
P/F ratio, median (IQR) 77.8 (54.6 - 115.7)
Admission laboratory results (reference range)
Urea (mmol/L) median (IQR) (2.1 - 7.1) 6.4 (4.5 - 9.0)
Creatinine (µmol/L), median (IQR) (64 - 104) 77 (63 - 107)
White cell count (× 109/L), mean (SD) (3.92 - 10.40) 12.0 (5.1)
Haemoglobin (g/dL), mean (SD) (13.0 - 17.0) 13.1 (1.8)
Platelet count (× 109/L), mean (SD) (171 - 388) 307.0 (117.2)
Absolute neutrophil count (× 109/L), mean (SD) (1.60 - 6.98) 10.0 (4.5)
Absolute lymphocyte count (× 109/L), mean (SD) (1.40 - 4.20) 1.1 (0.6)
Neutrophil to lymphocyte ratio, mean (SD) 11.8 (8.3)
Absolute eosinophil count (× 109/L), median (IQR) (0.00 - 0.95) 0.02 (0.01 - 0.04)
C-reactive protein (mg/L), mean (SD) (<10) 207 (119)
Procalcitonin (µg/L), median (IQR) (<0.1) 0.45 (0.20 - 1.09)
International normalised ratio, median (IQR) 1.13 (1.05 - 1.2175)
D-dimer (mg/L), median (IQR) (0.00 - 0.25) 1.08 (0.46 - 5.7)
HbA1c (%), median (IQR) 6.7 (6.2 - 9.5)
Troponin T (ng/L), median (IQR) (≤14) 13 (8 - 32)
ProB-type natriuretic peptide (ng/L), median (IQR) (<300) 350 (96 - 1 223)
Ferritin (µg/L), median (IQR) (30 - 400) 1 094 (689 - 1 744)
Alanine transaminase (U/L), median (IQR) (10 - 40) 31 (21 - 50)
SD = standard deviation; IQR = interquartile range; PaO2 = arterial oxygen partial pressure; P/F ratio = ratio of PaO2 to the fraction of inspired oxygen;  
HbA1c = glycated haemoglobin. 
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tracheal aspirates were 6.0 times (95% CI 2.6 - 13.6) more likely to 
be positive than early tracheal aspirates (p<0.0001) and late urine 
cultures were 3.0 times (95% CI 1.1 - 8.1) more likely to be positive 
than early urine cultures (p=0.03).
We identified over 20 different pathogens (Table 2 and Table  S2 
and Figs S1 - S3 in the Appendix (http://samj.org.za/public/
sup/15590.pdf)), the most common being Acinetobacter baumannii, 
Enterococcus faecalis, Klebsiella species and CoNS. The organisms 
identified in early cultures were different from those found in late 
cultures. CoNS was the most frequent organism in the first 2 days and 
A. baumannii thereafter.
Risk factors for positive culture
After adjusting for covariates, length of ICU stay, intubation and later 
pandemic time were associated with positive culture for a pathogen, 
while the number of concurrently admitted patients showed a slight 
protective effect. Disease severity on admission, age, comorbidities 
and early antibiotic use were not associated with coinfection or 
superinfection (Table 3).
Association of culture results with mortality and  
length of stay
Positive blood culture for pathogens showed a trend towards 
increased odds of mortality (OR 7.71; 95% CI 0.963 - 100.172; 
p=0.08) and was associated with longer ICU stay (mean (SD) 
15.8 (3.2) days compared with 9.5 (0.7) days for patients without 
a positive culture; p=0.0002). The most common organism, 
A. baumannii, was associated with a 6.6 times (95% CI 1.5 - 29.1) 
increased odds of mortality (p=0.004).
A positive pathogen culture on urine was not associated with 
mortality (p=1), but was associated with longer ICU stay (mean 
(SD) 17.9 (6.4) days v. 10.3 (0.8) days; p=0.02) when compared with 
patients with a negative urine culture.
A positive pathogen culture on tracheal aspirate was associated 
with increased odds of mortality (OR 34.1; 95% CI 2.013 - 818.06; 
p<0.05) and with a longer ICU stay (mean (SD) 16.3 (4.4) days, 
compared with 9.9 (0.8) days for patients with no growth; p=0.006).
Other risk factors associated with mortality were P/F ratio, 
intubation and age (Table 3).
People living with HIV
HIV infection was not associated with higher odds of positive blood 
culture (p=0.6), tracheal aspirate (p=0.8) or urine culture (p=1) for 
pathogens.
The most common pathogen identified in this group of patients 
was A. baumannii (n=9). There were single occurrences of CoNS, 
K. pneumoniae, E. faecalis, Candida glabrata, Enterobacter cloacae, 
K. oxytoca, Escherichia coli, Pseudomonas fluorescens and Bacteroides 
caccae.
Antibiotic use and resistance
A high rate of empirical antibiotic use was prescribed early in 
the pandemic as per unit protocol (see ‘Methods’). Amoxicillin-
clavulanate, azithromycin and meropenem were predominantly 
used. The use of these antibiotics decreased in the latter half of the 
pandemic, following a unit policy change as shown in Fig. 1.
The presence of antibiotic resistance was noted predominantly in 
the latter half of the pandemic, as shown in Fig. 2. We also observed 
Table 2. Frequency of cultured pathogens (n) by culture site and timing of culture during intensive care unit admission
Organism
Blood culture Tracheal aspirate Urine culture
Early Late Early Late Early Late
Gram-negative organisms
Acinetobacter baumannii 0 24 1 27 0 2
Klebsiella species 0 4 1 6 0 2
Pseudomonas aeruginosa 0 3 0 2 0 0
Escherichia coli 0 0 0 0 3 2
Enterobacter cloacae 1 3 0 1 0 0
Stenotrophomonas maltophilia 0 3 1 0 0 0
Serratia marcescens 0 2 0 1 0 0
Proteus mirabilis 0 1 0 0 0 1
Haemophilus influenzae 0 0 0 1 0 0
Pseudomonas fluorescens 0 1 0 0 0 0
Chryseobacterium indologenes 0 1 0 0 0 0
Morganella morganii 0 1 0 0 0 0
Gram-positive organisms
Coagulase negative staphylococci 5 4 0 0 0 0
Enterococcus faecalis 1 5 0 0 2 4
E. faecium 0 3 0 0 0 3
Bacillus species 0 3 0 0 0 0
Staphylococcus epidermidis 0 1 0 0 0 0
Anaerobes
Mycobacterium tuberculosis 0 0 1 1 0 0
Clostridium perfringens 0 1 0 0 0 0
Bacteroides caccae 0 0 1 0 0 0
Yeasts
Candida species 2 3 0 0 0 0
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an outbreak of XDR and PDR A. baumannii 
in the same period. Because of this and the 
short time frame of the study, no further 
statistical analysis on the evolution of 
antibiotic resistance was performed.
Early empirical antibiotics within the first 
48 hours of admission were prescribed to 
258 of the 363 adult patients included. We 
found no benefit from early antibiotic use, 
which was associated with a 2.06 times 
(95% CI 1.293 - 3.286) increased odds of 
mortality (p<0.01) in unadjusted analysis. 
The strength of this association was lost after 
adjusting for covariates (p=0.069), as shown 
in Table 3.
Discussion
We observed low rates (5.5%) of early 
bacterial coinfection in patients admitted 
with severe COVID-19, despite routine 
cultures being performed on admission to 
the ICU. There were also low rates of bacterial 
coinfection overall, with few organisms 
traditionally associated with community-
acquired pneumonia cultured.[6,9] However, 
when pathogens were identified on culture, 
they were associated with poor outcomes. We 
failed to demonstrate an association between 
Table 3. Risk factors for adverse outcomes in patients with COVID-19 admitted to the ICU, adjusted for covariates
Unadjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Risk factors for positive culture
Length of ICU stay 1.07 1.042 - 1.109 <0.001 1.09 1.048 - 1.134 <0.001
P/F ratio 1.00 0.997 - 1.003 0.905 1.00 0.99 - 1.002 0.547
Diabetes mellitus 0.81 0.504 - 1.299 0.383 0.65 0.365 - 1.16 0.1483
Early antibiotic use 0.87 0.521 - 1.457 0.578 1.29 0.659 - 2.59 0.461
Concurrently admitted patients 0.98 0.951 - 1.007 0.131 0.94 0.901 - 0.981 <0.01
Intubated 7.03 4.02 - 12.899 <0.001 8.5 4.567 - 16.766 <0.001
HIV-positive 0.93 0.46 - 1.794 0.844 0.95 0.412 - 2.084 0.898
Age 1.03 1.002 - 1.05 <0.05 1.02 0.99 - 1.042 0.119
Pandemic time 1.01 1.005 - 1.02 <0.01 1.02 1.006 - 1.026 <0.01
Risk factors for mortality
Resistance
MDR 2.31 0.548 - 15.708 0.30 2.05 0.095 - 36.983 0.631
XDR 11.24 2.262 - 203.855 <0.05 39.48 0.276 - 59 396.547 0.348
PDR 2.83 1.272 - 7.206 <0.05 0.16 0.008 - 3.666 0.241
Length of ICU stay 0.88 0.839 - 0.91 <0.001 0.74 0.668 - 0.797 <0.001
P/F ratio 1.00 0.991 - 0.998 <0.01 0.99 0.984 - 0.998 <0.05
Diabetes mellitus 1.31 0.855 - 2.027 0.213 1.17 0.538 - 2.539 0.691
Early antibiotic use 2.06 1.293 - 3.286 <0.01 2.48 0.948 - 6.814 0.069
Concurrently admitted patients 1.05 1.017 - 1.074 <0.01 1.03 0.966 - 1.105 0.355
Intubated 22.71 12.371 - 44.875 < 0.001 191.3 48.157 - 1 107.636 <0.001
Positive blood culture 3.66 1.867 - 7.873 <0.001 7.71 0.963 - 100.172 0.082
Positive tracheal aspirate 4.66 1.945 - 13.821 <0.01 34.1 2.013 - 818.06 <0.05
HIV-positive 1.47 0.791 - 2.872 0.236 3.08 0.958 - 10.452 0.064
Age 1.03 1.013 - 1.056 <0.01 1.05 1.011 - 1.094 <0.05
Pandemic time 1.0 0.997 - 1.011 0.239 0.99 0.978 - 1.011 0.533
OR = odds ratio; CI = confidence interval; ICU = intensive care unit; P/F ratio = ratio of arterial oxygen partial pressure to fraction inspired concentration of oxygen;  












































































































   
   
   
   
   
   
   




























Fig. 1. Number of patients receiving each antimicrobial agent, by day, 26 March - 31 August 2020.
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HIV and bacterial coinfection in COVID-19. 
Early empirical use of antibiotics in patients 
with confirmed COVID-19 pneumonia was 
not associated with improved outcomes 
(mortality or length of stay) and may have 
contributed to the observed emergence of 
resistant organisms in the second half of 
the study period, although an outbreak of 
A. baumannii – endemic at our institution, 
and which occurred during the pandemic in 
spite of strict personal protective equipment 
(PPE) policies and availability – also played 
a role. The outbreak may have skewed 
the temporal relationship, distribution of 
organisms and resistance patterns found.[24] 
A. baumannii was also the most frequently 
identified organism, cultured as early as 
patient day 3 and peaking at days 5 - 7, 
suggesting early colonisation on or before 
arrival in the ICU.
The finding of low numbers of early 
positive cultures for pathogens suggests 
that the presentation of severe COVID-
19 in this population is probably due to 
the effects of the SARS-CoV-2 virus itself, 
rather than any bacterial coinfection, as may 
occur with influenza.[9] Unit policy initially 
dictated empirical therapy with amoxicillin-
clavulanate and azithromycin for all 
severe presumed COVID-19 pneumonia, 
and a lack of microbiological evidence of 
early coinfection in our cohort provides 
a biological explanation for the failure of 
this strategy to improve outcomes. Instead, 
we found that early antibiotic therapy was 
paradoxically associated with increased 
mortality. However, many confounding 
factors may have influenced this observa-
tion, including patients being more severely 
ill or being treated earlier in the pandemic 
when we had less experience and fewer 
resources were available.
Our study contributes to a growing 
body of literature suggesting that bacterial 
coinfection and superinfection are 
uncommon in COVID-19 and that early 
use of empirical antibiotic therapy in these 
patients, in the absence of a specific bacterial 
infection, is unnecessary and potentially 
harmful.[10-12,16,17] Some authors have 
speculated about an increased rate of fungal 
coinfection in our setting, and possible 
excess mortality associated with it, but this 
has not been borne out in our study.[14]
Positive blood and respiratory cultures 
(but not urine cultures) demonstrated 
associations with mortality and length of 
stay. Strikingly, positive tracheal aspirates 
were more strongly associated with mortality 
(p<0.05) than positive blood cultures 
(p=0.082), although the small proportion 
of patients with positive cultures may be 
a reason for failing to reach statistical 
significance with the latter. Strategies to 
avoid bacterial coinfection are therefore 
vitally important in patients with COVID-
19. Intubation was independently associated 
with infection, and this may in part explain 
the success reported by some institutions 
using oxygenation strategies that avoid 
intubation, such as high-flow nasal prong 
oxygen.[22]
The lack of association between HIV 
and bacterial coinfection or superinfection 
during COVID-19 in our population is 
also noteworthy (p=0.9). However, caution 
must be exercised when interpreting this 
finding owing to the small size of the HIV-
positive subpopulation, and inherent bias 
when allocating scarce ICU resources to 
patients with better virological suppression 
and higher CD4 counts (i.e. more immuno-
competent individuals), as well as other 
possible unassessed confounders. [25] Simi-
larly, we did not find associations between 
diabetes and bacterial co-infection or 
superinfection, and only ICU length of 
stay, intubation and pandemic time showed 
significant associations with positive culture 
results for pathogens, while severity of illness 
did not.
Despite the compulsory use of PPE, 
there was a clear emergence of drug-
resistant organisms in the latter half of the 
pandemic, predominantly A.  baumannii, 
which has also been reported at other 
institutions experiencing a surge in COVID-
19 admissions to the ICU.[24] There are 
many likely factors contributing to this 
observation, including abnormally high 
patient loads and patient-to-staff ratios, 
high turnover of beds and staff, increased 
antibiotic use and PPE fatigue. In response 
to the COVID-19 pandemic, a significant 
effort was made to improve PPE for staff. 
Despite this, hospital-acquired infection 
remained the biggest contributor to the 
bacterial pathogens isolated during the study 
period. We postulate that the increased use 
of PPE, perceived to protect staff rather 
than patients, paradoxically increased the 
likelihood of contamination by serving 
as a vector for transfer of organisms, 
and standard infection control measures 
(e.g. handwashing, glove changing and 
meticulous cleaning of equipment) should 
not be forgotten. Multivariate analysis was 
not able to confirm the association between 
antibiotic resistance and mortality seen on 
unadjusted analysis, suggesting a complex 
interaction of confounding factors.
As evidence to the contrary accumulates, 
future guidelines for the inpatient manage-
ment of COVID-19 need to reconsider 
the blanket recommendation to prescribe 
empirical antibiotics to all critically 
ill COVID-19 patients. A subgroup of 
patients with coinfection may exist and 
require antibiotics. However, traditional 
inflammatory markers may be raised by 
COVID-19 itself and may not be helpful 
in identifying these patients. In particular, 
while a low procalcitonin (PCT) level 
provides confidence to omit antibiotics, 
high PCT does not necessarily imply the 
presence of bacterial infection and need for 
Fig. 2. Resistance profiles of isolates over the course of the pandemic, 26 March - 31 August 2020. 
(PDR = pan-drug resistance; XDR = extensive drug resistance; MDR = multidrug resistance.)
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antibiotics. [1,3,4] Further research is needed to identify specific cut-
off thresholds in COVID-19 patients. Other studies are needed to 
confirm our findings, in particular the lack of association with HIV 
and bacterial coinfection and superinfection in COVID-19. Standard 
infection control measures should not be seen to be replaced by 
PPE where COVID-19 patients are cohorted, and clinicians should 
be aware of the potential for emergence of antibiotic-resistant 
organisms, especially during a pandemic.
Study limitations
While all patients have cultures performed on admission to the ICU 
according to institutional protocol, repeat cultures are performed 
only when clinically indicated and not routinely. Assessing whether 
organisms are contaminants, colonisers or pathogens is also 
imprecise. Indeed, organisms such as CoNS and B. cereus are 
frequently contaminants but may also cause infection, and this 
distinction can be difficult in critically ill patients, even at the 
bedside. The number of infections analysed in this study could 
therefore be either over- or under-inflated. For example, despite 
our strategy for removing potential contaminants, CoNS remained 
the most frequently identified organism during the first 2 days 
of ICU admission. No molecular testing was done to confirm the 
A. baumannii outbreak, as this was detected retrospectively. As in any 
study in an ICU, our findings are subject to the heterogeneity of the 
patients and many known and unknown confounders. Associations 
do not necessarily imply causality or prediction.
Conclusions
Bacterial co-infection is rare at the time of ICU admission with 
COVID-19, supporting a strategy of withholding early empirical 
antibiotic therapy, which may help to limit antimicrobial resistance. 
Late infection after 2 days of admission was more common than 
early infection and was associated with intubation, length of stay 
and mortality. Infection prevention and control bundles, strict use 
of PPE to protect both patients and staff from nosocomial infections 
and outbreaks, and oxygenation strategies that avoid intubation may 
therefore prove to be important aspects of COVID-19 care.
Declaration. None.
Acknowledgements. The authors wish to acknowledge the efforts and 
sacrifices of all staff working in the Tygerberg Hospital COVID-19 
unit, and our patients, who remain our greatest teachers. The authors 
specifically acknowledge Nicola Baines, Vera Ngah and Patricia Maud for 
their tireless efforts in data collection.
Author contributions. MSM was responsible for concept, literature 
review, data collection, data analysis and manuscript completion. BWA 
was responsible for concept, data collection, manuscript completion 
and manuscript approval. IF and PSN were responsible for data analysis, 
manuscript completion and manuscript approval. KR, JJT, AP, EHL, AN, 




1. Parker A, Koegelenberg CF, Moolla M, et al. High HIV prevalence in an early cohort of hospital 
admissions with COVID-19 in Cape Town, South Africa. S Afr Med J 2020;110(10):982-987. https://
doi.org/10.7196/SAMJ.2020.v110i10.15067
2. Moolla M, Parker A, Parker M, et al. Staff testing for coronavirus disease 2019 via an online pre-
registration form. S Afr J Infect Dis 2020;36(1):a232. https://doi.org/10.4102/sajid.v36i1.232
3. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J 
Med 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
4. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with 
covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational 
cohort study. BMJ 2020;369:m1985. https://doi.org/10.1136/bmj.m1985
5. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 – 
preliminary report. N Engl J Med 2020;384(8):693-704. https://doi.org/10.1056/NEJMoa2021436
6. Boyles TH, Brink A, Calligaro GL, et al. South African guideline for the management of community-
acquired pneumonia in adults. J Thorac Dis 2017;9(6):1469-1502. https://doi.org/10.21037/
jtd.2017.05.31
7. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the 
management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 
2020;46(5):854-887. https://doi.org/10.1007/s00134-020-06022-5
8. Richards G, Mer M, Schleicher G, et al. COVID-19 and the rationale for pharmacotherapy: A South 
African perspective. Wits J Clin Med 2020;2(S1):11-18. https://doi.org/10.18772/26180197.2020.
v2nSIa2
9. Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: Illuminating 
the immunologic mechanisms of disease. Infect Immun 2015;83(10):3764-3770. https://doi.
org/10.1128/IAI.00298-15
10. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients 
with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect 2020 (epub 22 July 
2020). https://doi.org/10.1016/j.cmi.2020.07.016
11. Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: A systematic review 
and meta-analysis. SSRN 2020 (epub 11 June 2020). https://doi.org/10.2139/ssrn.3594598
12. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients 
with COVID-19. Intensive Care Med 2020;46(11):2071-2074. https://doi.org/10.1007/s00134-020-
06219-8
13. Simbayi L, Zuma K, Zungu N, et al. South African National HIV Prevalence, Incidence, Behaviour 
and Communication Survey, 2017. Cape Town: HSRC Press, 2018. https://www.hsrcpress.
ac.za/books/south-african-national-hiv-prevalence-incidence-behaviour-and-communication-
survey-2017 (accessed 30 November 2020).
14. Ezeokoli OT, Pohl CH. Opportunistic pathogenic fungal co-infections are prevalent in critically ill 
COVID-19 patients: Are they risk factors for disease severity? S Afr Med J 2020;110(11):1081-1085. 
https://doi.org/10.7196/SAMJ.2020.v110i11.15248
15. Parker A, Shaw J, Karamchand S, et al. HIV and SARS-CoV-2 co-infection: The diagnostic 
challenges of dual pandemics. S Afr Med J 2020;110(6):473-475. https://doi.org/10.7196/SAMJ.2020.
v110i6.14825
16. Clancy CJ, Nguyen MH. Coronavirus disease 2019, superinfections, and antimicrobial development: 
What can we expect? Clin Infect Dis 2020;71(10):2736-2743. https://doi.org/10.1093/cid/ciaa524
17. Buetti N, Mazzuchelli T, Lo Priore E, et al. Early administered antibiotics do not impact mortality 
in critically ill patients with COVID-19. J Infect 2020;81(2):e148-e149. https://doi.org/10.1016/j.
jinf.2020.06.004
18. Tamma PD, Avdic E, Li DX, et al. Association of adverse events with antibiotic use in 
hospitalized patients. JAMA Intern Med 2017;177(9):1308-1315. https://doi.org/10.1001/
jamainternmed.2017.1938
19. Paruk F, Richards G, Scribante J, et al. Antibiotic prescription practices and their relationship to 
outcome in South Africa: Findings of the prevalence of infection in South African intensive care 
units (PISA) study. S Afr Med J 2012;102(7):613-616.
20. Bamford C, Bonorchis K, Elliott E, et al. Antimicrobial susceptibility patterns of selected bacteraemic 
isolates from public sector hospitals in South Africa. South Afr J Epidemiol Infect 2009;24(4):28-30. 
https://doi.org/10.1080/10158782.2011.11441461
21. Allwood BW, Koegelenberg CFN, Irusen E, et al. Clinical evolution, management and outcomes 
of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: A research 
protocol. BMJ Open 2020;10:e039455. https://doi.org/10.1136/bmjopen-2020-039455
22. Lalla U, Allwood BW, Louw EH, et al. The utility of high-flow nasal cannula oxygen therapy 
in the management of respiratory failure secondary to COVID-19 pneumonia. S Afr Med J 
2020;110(6):432. https://doi.org/10.7196/SAMJ.2020.v110i6.14882
23. Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant 
and pandrug-resistant bacteria: An international expert proposal for interim standard definitions 
for acquired resistance. Clin Microbiol Infect 2012;18(3):268-281. https://doi.org/10.1111/j.1469-
0691.2011.03570.x
24. Perez S, Innes GK, Walters MS, et al. Increase in hospital-acquired carbapenem-resistant 
Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in 
COVID-19 admissions – New Jersey, February - July 2020. MMWR Morb Mortal Wkly Rep 
2020;69(48):1827-1831. https://doi.org/10.15585/mmwr.mm6948e1
25. Singh JA, Moodley K. Critical care triaging in the shadow of COVID-19: Ethics considerations. S Afr 
Med J 2020;110(5):355-359. https://doi.org/10.7196/SAMJ.2020.v110i5.14778
Accepted 18 March 2021.
